BioWorld

Nov. 20, 2006

View Archived Issues

FDA Approves Herceptin In Adjuvant Breast Cancer

The FDA granted a broader label to Herceptin (trastuzumab), paving the way for Genentech Inc. to promote its most visible targeted oncology product as a front-line treatment for breast cancer.(BioWorld Today) Read More

British Consolidation: Innovata Bought By Vectura For £131.9M

Read More

Filling The Pipeline: 'Early Stage' Firm Varies In Eyes Of Beholder

Read More

Advanced Magnetics Rises On Positive Phase III Data

Read More

Medicure Starts Pivotal Trial Of MC-1 In Bypass Patients

Read More

Other News To Note

Read More

Clinic Roundup

Read More